1
|
Vallentgoed WR, Hoogstrate Y, van Dijk E, van Garderen K, Niers A, van den Bent MJ, Draaisma K, van Eijk P, de Heer I, Kouwenhoven M, Kros JM, de Leng W, van Nee M, Robe P, Smits M, Tesileanu M, Westerman B, van de Wiel M, Ylstra B, Wesseling P, French PJ. OS08.1.A Integrative molecular analysis of matched primary and recurrent IDH-mutant astrocytoma; an update from the GLASS-NL consortium. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The evolutionary processes that drive tumor progression in patients with IDH-mutant astrocytoma remain largely unclear. The GLASS-NL consortium was initiated to gain insight into the molecular mechanisms underlying glioma evolution and to identify markers of progression in IDH-mutant astrocytomas. Ultimately, such markers can assist clinical decision making. Here, we present the DNA methylation profiling, RNA-sequencing and shallow whole-genome sequencing (sWGS) of samples included in the GLASS-NL study.
Methods
Eligible were patients with an IDH-mutant, 1p19q non-codeleted, astrocytoma at first diagnosis who underwent surgical resection of the tumor at least twice separated by >6 months, and of whom paired tumor samples were available for analyses. Overall survival (OS) was measured from date of initial surgery.
DNA methylation profiling was performed with the 850kEPIC array, and transcriptome and sWGS by NGS. After quality control, DNA methylation data of 103, expression data of 91, and sWGS data of 92 patients was available for further analysis. Methylation classes were determined according to Capper et al. and copy number alterations (CNAs) were extracted from both sWGS and DNA-methylation data.
Results
110 patients were identified from various medical centers in the Netherlands. The median time between surgical resections was 41.9 months (IQR:26.5-65.9) and after initial surgery, 63% and 22% of the patients were treated with radiotherapy or chemotherapy respectively. The proportion of samples assigned to the high grade methylation class increased ~three-fold at recurrence. 83% of patients that progressed from low to high grade, received treatment prior to recurrent surgery, as compared to 53% of the patients that remained low grade.
Genome wide DNA methylation levels of recurrent samples were lower than that of initial samples. This difference is explained by the increased number of high grades at recurrence, since near identical DNA methylation levels were observed in samples that remained low grade.
Analysis of CNAs revealed chromosomal arms that were more frequently altered in high grade samples. Univariate analysis showed that losses in 3p, 9p, 10q, 13q and 14q were associated with poor OS.
More than 800 differentially expressed genes between initial and recurrent tumor samples were found. Chromosomal enrichment analysis revealed a locus on chromosome 6 enriched with histone genes, to be significantly up-regulated over time.
Conclusion
Longitudinal methylation profiling of IDH-mutant astrocytoma reveals a shift towards a higher grade at tumor recurrence coinciding with reduced DNA methylation levels, and increased frequency of CNAs. Longitudinal expression analysis showed changes in expression of >800 genes, including an up-regulated locus enriched with histone genes. Further integrative analyses are ongoing and will be reported at the meeting.
Collapse
Affiliation(s)
| | | | | | | | - A Niers
- Amsterdam UMC , Amsterdam , Netherlands
| | | | | | | | - I de Heer
- Erasmus MC , Rotterdam , Netherlands
| | | | - J M Kros
- Erasmus MC , Rotterdam , Netherlands
| | | | - M van Nee
- Amsterdam UMC , Amsterdam , Netherlands
| | - P Robe
- UMC Utrecht , Utrecht , Netherlands
| | - M Smits
- Erasmus MC , Rotterdam , Netherlands
| | | | | | | | - B Ylstra
- Amsterdam UMC , Amsterdam , Netherlands
| | | | | |
Collapse
|
2
|
Vallentgoed WR, Niers JM, van den Bent MJ, Kouwenhoven MCM, Kros JM, Martin I, van Thuijl HF, van de Wiel MA, Wesseling P, French PJ. OS05.5.A Methylation analysis of matched primary and recurrent IDHmt astrocytoma; an update from the Glioma Longitudinal Analysis NL (GLASS-NL) consortium. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
BACKGROUND
The evolutionary processes that drive progression in patients with IDH-mutant astrocytoma remain unclear. The GLASS-NL consortium, as part of the larger worldwide GLASS consortium, was initiated to gain insight into the molecular mechanisms underlying glioma evolution and to identify markers of progression in IDH-mutant astrocytomas. Such markers can ultimately assist clinical decision making. Here, we present the first results of genome wide methylation profiling of samples included in the GLASS-NL study.
MATERIAL AND METHODS
110 adult patients were identified with an IDH-mutant astrocytoma at first diagnosis. All patients underwent a surgical resection of the tumor at least twice, separated by at least 6 months with a median of 40.9 months (IQR: 24.0, 64.7), in 37% and 18% of the cases, patients were treated with radiotherapy or chemotherapy respectively, before surgical resection of the recurrent tumor. Methylation profiling was done on (macro dissected) DNA isolated of 235 samples from 103 patients (102 1st, 101 2nd, 29 3rd, and 3 4th resection), using the Infinium MethylationEPIC BeadChip array. Copy number variations were also derived from these data. Methylation classes were determined according to Capper et al. (2018). Overall survival (OS) was measured from date of first surgery.
RESULTS
Of all primary tumors, the methylation-classifier assigned 85 (87%) to the A_IDH (‘low grade’) subclass and 10 (10%) to the A_IDH_HG (‘high grade’) subclass. The relative proportion of high grade tumors increased ~three-fold at tumor recurrence (32/101, 32%) and even further in the second recurrence (15/29, 52%). The overall DNA-methylation levels of recurrent samples was lower than that of primary samples. This difference is explained by the increased number of high grade samples at recurrence, since near identical DNA-methylation levels were observed in samples that remained low grade. In an unsupervised analysis, methylation data derived from first and second resections of individual patients mostly (79%) cluster together. This indicates that variability between tumors is larger than temporal heterogeneity within tumors. Recurrent samples that do not cluster with their primary tumor, form a separate cluster and have relatively low genome-wide DNA-methylation.
CONCLUSION
Our data demonstrate that methylation profiling identifies a shift towards a higher grade at tumor progression coinciding with reduced genome-wide DNA-methylation levels.
Collapse
Affiliation(s)
| | - J M Niers
- Amsterdam UMC/VUmc, Amsterdam, Netherlands
| | | | | | - J M Kros
- Erasmus MC, Rotterdam, Netherlands
| | - I Martin
- Amsterdam UMC/VUmc, Amsterdam, Netherlands
| | | | | | - P Wesseling
- Amsterdam UMC/VUmc, Amsterdam, Netherlands
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
| | | |
Collapse
|